Clinical evaluation of a novel microneedle device for intradermal delivery of an influenza vaccine: Are all delivery methods the same?

Levin, Yotam; Kochba, Efrat; Kenney, Richard T.

doi:10.1016/j.vaccine.2014.03.024

Cited by 66 publications

(43 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Participants had pretreatment blood sample and axillary LN FNA biopsy, followed by injection of a single dose of 2 tuberculin units (TU) PPD (Serum Statens Institute, Copenhagen, Denmark) by a hollow microneedle (Micronjet 600 Needle; Nanopass Technologies, Israel), which was previously used for vaccination in various clinical studies (20). The injection was administered intradermally in the forearm, contralateral to the initial LN FNA.…”

Section: Subjectsmentioning

confidence: 99%

Fine-Needle Aspiration Biopsy of the Lymph Node: A Novel Tool for the Monitoring of Immune Responses after Skin Antigen Delivery

Tatović

Young

Kochba³

et al. 2015

The Journal of Immunology

Self Cite

View full text Add to dashboard Cite

Assessment of immune responses in lymph nodes (LNs) is routine in animals, but rarely done in humans. We have applied minimally invasive ultrasound-guided fine-needle aspiration of the LN to a before-and-after study of the immune response to intradermally delivered Ag in healthy volunteers (n = 25). By comparison with PBMCs from the same individual, LN cells (LNCs) were characterized by reduced numbers of effector memory cells, especially CD8+ TEMRA cells (3.37 ± 1.93 in LNCs versus 22.53 ± 7.65 in PBMCs; p = 0.01) and a marked increased in CD69 expression (27.67 ± 7.49 versus 3.49 ± 2.62%, LNCs and PBMCs, respectively; p < 0.0001). At baseline, there was a striking absence of IFN-γ ELISPOT responses to recall Ags (purified protein derivative, Tetanus toxoid, or flu/EBV/CMV viral mix) in LN, despite strong responses in the peripheral blood. However, 48 h after tuberculin purified protein derivative administration in the ipsilateral forearm resulting in a positive skin reaction, a clear increase in IFN-γ ELISPOT counts was seen in the draining LN but not in PBMCs. This response was lost by 5 d. These data suggest that the low levels of effector memory cells in the LN may explain the low background of baseline ELISPOT responses in LNs as compared with PBMCs, and the appearance of a response after 48 h is likely to represent migration of effector memory cells from the skin to the LN. Hence, it appears that the combination of intradermal Ag administration and draining LN sampling can be used as a sensitive method to probe the effector memory T cell repertoire in the skin.

show abstract

Section: Subjectsmentioning

confidence: 99%

Fine-Needle Aspiration Biopsy of the Lymph Node: A Novel Tool for the Monitoring of Immune Responses after Skin Antigen Delivery

Tatović

Young

Kochba³

et al. 2015

The Journal of Immunology

Self Cite

View full text Add to dashboard Cite

show abstract

“…And the safety and effectiveness of these MA-based vaccines have been primarily confirmed by the updated clinical trials. 20,21,85 Also, a recent interview showed high support for administration of MA vaccines by key opinion leaders in the United States, who suggested that the priority considerations in the ongoing development of MA vaccines include confirming efficacy and ensuring safety for self-administration, ease of use, short wear times, and an easily accessible application site. 84 All these suggest that MA vaccines have attracted attentions not only from the academic and industrial communities but also from the governmental administrations, as also indicated by the fact that MAs combine with several conventional vaccines, such as influenza, polio and measles, have been approved for clinical trials under collaboration between researchers, manufacturers and the administrative authorities.…”

Section: Hopes and Prospects Of Mpma Vaccinesmentioning

confidence: 99%

“…To date, though various types of MPMA vaccines under development are still far away from markets, several conventional vaccines based on microneedle delivery-are undergoing clinical trials, [19][20][21][22][23] hinting the tantalizing prospects of MPMA products, which have numerous ideal features including the high stability, convenient and painless inoculation process, the possibility of self-administration, and easy post-use disposal leaving no needle pollutions. In this review, different types of MPMAs fabricated as an effective VADS are introduced to provide a reference to readers who are going to commit to the development of MA vaccines that are suitable for wide vaccination.…”

mentioning

confidence: 99%

Multifunctional particle-constituted microneedle arrays as cutaneous or mucosal vaccine adjuvant-delivery systems

Wang

et al. 2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

To overcome drawbacks of current injection vaccines, such as causing needle phobia, needing health professionals for inoculation, and generating dangerous sharps wastes, researchers have designed novel vaccines that are combined with various microneedle arrays (MAs), in particular, with the multifunctional particle-constructed MAs (MPMAs). MPMAs prove able to enhance vaccine stability through incorporating vaccine ingredients in the carrier, and can be painlessly inoculated by minimally trained workers or by selfadministration, leaving behind no metal needle pollution while eliciting robust systemic and mucosal immunity to antigens, thanks to delivering vaccines to cutaneous or mucosal compartments enriched in professional antigen-presenting cells (APCs). Especially, MPMAs can be easily integrated with functional molecules fulfilling targeting vaccine delivery or controlling immune response toward a Th1 or Th2 pathway to generate desired immunity against pathogens. Herein, we introduce the latest research and development of various MPMAs which are a novel but promising vaccine adjuvant delivery system (VADS).

show abstract

“…Different approaches of MNA technologies have all been confirmed feasible. For example, initial comparisons demonstrated the use of MNAs as very efficient for insulin delivery in type 1 diabetes patients as well as influenza vaccination or delivery of anti-TNFa antibodies in animal studies (Gupta et al,2009;Nordquist et al, 2007;Harvey et al, 2011;Levin et al, 2014;Norman et al, 2014).…”

Section: Introductionmentioning

confidence: 99%

Controlled release of a model vaccine by nanoporous ceramic microneedle arrays

Boks

Unger

Engels

et al. 2015

International Journal of Pharmaceutics

View full text Add to dashboard Cite

Clinical evaluation of a novel microneedle device for intradermal delivery of an influenza vaccine: Are all delivery methods the same?

Cited by 66 publications

References 16 publications

Fine-Needle Aspiration Biopsy of the Lymph Node: A Novel Tool for the Monitoring of Immune Responses after Skin Antigen Delivery

Fine-Needle Aspiration Biopsy of the Lymph Node: A Novel Tool for the Monitoring of Immune Responses after Skin Antigen Delivery

Multifunctional particle-constituted microneedle arrays as cutaneous or mucosal vaccine adjuvant-delivery systems

Controlled release of a model vaccine by nanoporous ceramic microneedle arrays

Contact Info

Product

Resources

About